TEDA Biomedical Swings to 1H26 Profit as AI Healthcare Drives 31% Revenue Growth

Bulletin Express
Aug 31

Tianjin TEDA Biomedical Engineering Company Limited (TEDA Biomedical) reported a marked turnaround for the six months ended 30 June 2026, underpinned by rapid expansion in its AI-driven life and health operations.

Revenue climbed 30.75% year on year to RMB 296.03 million, propelled by a 145% surge in AI health and elderly-care products and services to RMB 106.37 million. Fertiliser sales edged up 3.65% to RMB 189.67 million despite industry headwinds.

Gross profit more than doubled, advancing 141.40% to RMB 33.36 million, lifting the gross margin to 11.27% from 6.10% a year earlier. Tight cost control contributed to a 19.09% reduction in selling and distribution expenses to RMB 3.20 million and a 20.39% fall in combined R&D and administrative expenses to RMB 13.18 million. Finance costs declined 22.30% to RMB 1.53 million.

The Group recorded a profit attributable to equity holders of RMB 10.21 million, reversing a RMB 6.43 million loss in 1H25; basic earnings per share were RMB 0.048 cents. Net profit for the period totalled RMB 14.88 million, buoyed by the scaling of the “Xihe No.1” medical large model and related data-software sales.

Cash and bank balances more than doubled to RMB 65.30 million, supported by RMB 37.50 million net cash from operations. Short-term borrowings were broadly stable at RMB 97.84 million, while the gearing ratio improved to 0.22 from 0.37 at end-2025. The asset-liability ratio moderated to 0.94. Net current liabilities widened to RMB 79.18 million, reflecting higher trade and contract payables linked to the AI rollout.

Capital expenditure remained modest at RMB 1.01 million. Intangible assets rose to RMB 45.32 million, consistent with ongoing capitalisation of AI R&D outlays. No interim dividend was declared.

Strategically, TEDA Biomedical accelerated its pivot from traditional fertilisers toward AI-enabled healthcare. Key initiatives included city-level deployments of the “Xihe No.1” medical model in Yinchuan and Xiamen, development of the “Helan Mountain No.1” full-stack AI industry model, and construction of Yinchuan’s “One Cloud, One Lake, One Platform” public data operations infrastructure.

Governance changes featured the appointment of Ms Lynn Li as joint CEO alongside Ms Sun Li, who remains Chair and now serves as joint CEO. Executive director Mr Xia Alan Zhe was redesignated as a non-executive director following regulatory considerations.

Management reiterated its commitment to expanding AI-based medical solutions nationwide and deepening integration with elderly-care services, while continuing to streamline its fertiliser operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10